Literature DB >> 29777229

Fate of the metabolically healthy obese-is this term a misnomer? A study from the Clinical Practice Research Datalink.

Osama Moussa1, Chanpreet Arhi2, Paul Ziprin2, Ara Darzi2, Omar Khan3,4, Sanjay Purkayastha2.   

Abstract

INTRODUCTION: The metabolically healthy obese (MHO) phenotype may express typical characteristics on long-term follow-up. Little is known about the initiation of this phenotypes and its future stability. AIM: The Clinical Practice Research Datalink (CPRD) is a large-scale primary care database. The aim of this study was to assess the stability of, and evaluate the factors associated with a transition into an unhealthy outcome in, a MHO population in the UK.
METHODS: The CPRD was interrogated for a diagnosis of 'obesity' and cross-referenced with a body mass index (BMI) ≥35 kg/m2; participants were further classified as MH using a clinical diagnostic code or a relative therapeutic code. A hazard cox regression univariate and multivariate analysis evaluated the time to transition for independent variables.
RESULTS: There were 231,399 patients with a recorded BMI of 35 kg/m2 or greater. Incomplete records were eliminated and follow-up limited to 300 months, the cohort was reduced to 180,560 patients. The prevalence of MHO within the obese population from the CPRD was 128,191/180,560 (71%). MHO individuals, who were of male gender (hazard ratio (HR) 1.23 (1.21-1.25), p = < 0.01), older age group (HR 3.93 (3.82-4.04), p = < 0.01), BMI of 50-60 kg/m2 at baseline (HR 1.32(1.26-1.38), p = 0.01), smokers (HR 1.07(1.05-1.09), p = < 0.01) and regionally from North West England (HR 1.15(1.09-1.21), p = < 0.01) were more prone to an unhealthy transition (to develop comorbidities). Overall, of those MH at baseline, 71,485/128,191(55.8%) remained healthy on follow-up, with a mean follow-up of 113.5 (standard deviations (SD) 78.6) months or 9.4 (SD 6.6) years.
CONCLUSIONS: From this unique large data set, there is a greater prevalence of MHO individuals in the UK population than in published literature elsewhere. Female gender, younger age group, and lower initial weight and BMI were found to be significant predictors of sustained metabolic health in this cohort. However, there remains a steady progressive transition from a healthy baseline over the years.

Entities:  

Mesh:

Year:  2018        PMID: 29777229     DOI: 10.1038/s41366-018-0096-z

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  6 in total

Review 1.  Metabolically Healthy Obesity and Bariatric Surgery.

Authors:  Adriana Florinela Cătoi; Luca Busetto
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

Review 2.  Metabolically healthy obesity: facts and fantasies.

Authors:  Gordon I Smith; Bettina Mittendorfer; Samuel Klein
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 3.  Metabolically Healthy Obesity.

Authors:  Matthias Blüher
Journal:  Endocr Rev       Date:  2020-05-01       Impact factor: 19.871

4.  The Association Between Metabolic Status and Risk of Cancer Among Patients With Obesity: Metabolically Healthy Obesity vs. Metabolically Unhealthy Obesity.

Authors:  Xiaonan Zheng; Ruilin Peng; Hang Xu; Tianhai Lin; Shi Qiu; Qiang Wei; Lu Yang; Jianzhong Ai
Journal:  Front Nutr       Date:  2022-02-25

5.  Clinical monitored in subjects metabolically healthy and unhealthy before and during a SARS-CoV-2 infection- A cross-sectional study in Mexican population.

Authors:  Samuel Treviño; Steffany Cortezano-Esteban; Hugo Hernández-Fragoso; Alfonso Díaz; Rubén Vázquez-Roque; Victor Enrique Sarmiento-Ortega; Diana Moroni-González; Rosana Pelayo; Eduardo Brambila
Journal:  Cytokine       Date:  2022-03-28       Impact factor: 3.861

6.  Factors related to overweight and obese populations maintaining metabolic health.

Authors:  Yi-Hsuan Lin; Hsiao-Ting Chang; Yen-Han Tseng; Harn-Shen Chen; Shu-Chiung Chiang; Tzeng-Ji Chen; Shinn-Jang Hwang
Journal:  PeerJ       Date:  2022-04-12       Impact factor: 3.061

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.